A carregar...
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
Median survival for patients with metastatic pancreatic cancer (MPC) treated with combination chemotherapeutic agents such as gemcitabine-based regimens and FOLFIRINOX is currently less than 12 months. This highlights the need for more efficacious first-line, as well as second-line therapies. Nanoli...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5484436/ https://ncbi.nlm.nih.gov/pubmed/28804517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X17705328 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|